Safety of MT-401-OTS in Patients With Relapsed AML or MDS
Status:
RECRUITING
Trial end date:
2029-09-01
Target enrollment:
Participant gender:
Summary
This study is a Phase 1 multicenter, open-label study evaluating the safety and efficacy of escalating doses of MT-401-OTS in 2 participant populations: 1) Those with intermediate or high-risk AML per 2022 ELN criteria who have evidence of MRD and/or \Phase:
PHASE1
Details
Lead Sponsor:
Marker Therapeutics, Inc.
Collaborators:
City of Hope National Medical Center H. Lee Moffitt Cancer Center and Research Institute University of Kansas Medical Center